Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3.
Aged
Autophagy
/ drug effects
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Culture Media, Conditioned
/ metabolism
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Interferon-gamma
/ genetics
Janus Kinase 2
/ antagonists & inhibitors
Male
Middle Aged
Monoclonal Gammopathy of Undetermined Significance
/ drug therapy
Multiple Myeloma
/ drug therapy
Neutrophils
/ drug effects
Nitriles
Phosphorylation
/ drug effects
Pyrazoles
/ pharmacology
Pyrimidines
Reactive Oxygen Species
/ metabolism
STAT3 Transcription Factor
/ genetics
Signal Transduction
/ drug effects
IFN-γ
STAT-3
autophagy
neutrophil
ruxolitinib
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
19 Jul 2019
19 Jul 2019
Historique:
received:
06
06
2019
revised:
13
07
2019
accepted:
16
07
2019
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
7
7
2020
Statut:
epublish
Résumé
In both monoclonal gammopathy of uncertain significance (MGUS) and multiple myeloma (MM) patients, immune functions are variably impaired, and there is a high risk of bacterial infections. Neutrophils are the most abundant circulating leukocytes and constitute the first line of host defense. Since little is known about the contribution of autophagy in the neutrophil function of MGUS and MM patients, we investigated the basal autophagy flux in freshly sorted neutrophils of patients and tested the plastic response of healthy neutrophils to soluble factors of MM. In freshly sorted high-density neutrophils obtained from patients with MGUS and MM or healthy subjects, we found a progressive autophagy trigger associated with soluble factors circulating in both peripheral blood and bone marrow, associated with increased IFNγ and pSTAT3S727. In normal high-density neutrophils, the formation of acidic vesicular organelles, a morphological characteristic of autophagy, could be induced after exposure for three hours with myeloma conditioned media or MM sera, an effect associated with increased phosphorylation of STAT3-pS727 and reverted by treatment with pan-JAK2 inhibitor ruxolitinib. Taken together, our data suggest that soluble factors in MM can trigger contemporary JAK2 signaling and autophagy in neutrophils, targetable with ruxolitinib.
Identifiants
pubmed: 32565533
pii: ijms20143548
doi: 10.3390/ijms20143548
pmc: PMC6678548
pii:
doi:
Substances chimiques
Culture Media, Conditioned
0
IFNG protein, human
0
Nitriles
0
Pyrazoles
0
Pyrimidines
0
Reactive Oxygen Species
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Interferon-gamma
82115-62-6
ruxolitinib
82S8X8XX8H
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG22131
Organisme : Società Italiana di Ematologia Sperimentale
ID : NA
Organisme : Collegio Ghislieri di Pavia
ID : NA
Références
Biomed Res Int. 2014;2014:198539
pubmed: 25013764
Sci Rep. 2019 Feb 6;9(1):1509
pubmed: 30728369
Ann Hematol. 2018 Jun;97(6):1009-1018
pubmed: 29442162
Am J Respir Cell Mol Biol. 2015 Mar;52(3):349-64
pubmed: 25100610
Transl Oncol. 2018 Dec;11(6):1350-1357
pubmed: 30196237
Mol Immunol. 2004 Jul;41(6-7):631-43
pubmed: 15220000
Cancer. 1992 Mar 15;69(6):1373-6
pubmed: 1540875
Leukemia. 2011 Mar;25(3):538-50
pubmed: 21164517
Cancer Lett. 2016 Feb 1;371(1):117-24
pubmed: 26639197
JAKSTAT. 2013 Jul 1;2(3):e24353
pubmed: 24069557
Ann Clin Lab Sci. 2008 Summer;38(3):241-6
pubmed: 18715852
Cancer Cell. 2015 Aug 10;28(2):253-69
pubmed: 26267538
Blood. 1995 Jan 15;85(2):487-94
pubmed: 7812003
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
J Immunol. 2012 Jul 15;189(2):813-8
pubmed: 22675202
Neoplasia. 2010 Jan;12(1):28-38
pubmed: 20072651
Immunity. 2017 Sep 19;47(3):466-480.e5
pubmed: 28916263
Shock. 2007 Jan;27(1):55-60
pubmed: 17172981
Int J Mol Sci. 2017 Jun 16;18(6):
pubmed: 28621712
Autophagy. 2012 Jun;8(6):989-91
pubmed: 22722139
Blood. 2019 May 16;133(20):2140-2148
pubmed: 30898859
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6674-9
pubmed: 11390994
Blood. 2014 Jun 12;123(24):3797-802
pubmed: 24778152
Front Cell Dev Biol. 2018 Sep 04;6:109
pubmed: 30234114
Oncotarget. 2016 Dec 27;7(52):85764-85775
pubmed: 26967390
J Exp Med. 2014 Sep 22;211(10):1993-2011
pubmed: 25225462
Ann Hematol. 2019 Mar;98(3):691-703
pubmed: 30635766
Cell Rep. 2015 Feb 3;10(4):562-73
pubmed: 25620698
Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12952
pubmed: 29772063
Cancer Biol Ther. 2017 Aug 3;18(8):584-595
pubmed: 28718729
Front Immunol. 2016 Nov 04;7:484
pubmed: 27867387
Clin Cancer Res. 2011 Mar 15;17(6):1243-52
pubmed: 21411440
Cell Death Differ. 2015 Mar;22(3):445-56
pubmed: 25323583
J Immunol. 2003 Feb 15;170(4):1964-72
pubmed: 12574365
Ann Hematol. 2015 Nov;94(11):1875-83
pubmed: 26223359
Mol Cell. 2012 Dec 14;48(5):667-80
pubmed: 23084476
Sci Rep. 2015 Nov 09;5:15701
pubmed: 26549519
PLoS One. 2011;6(12):e29318
pubmed: 22195044
Nat Rev Clin Oncol. 2019 Oct;16(10):601-620
pubmed: 31160735
Br J Haematol. 1994 Apr;86(4):726-32
pubmed: 7918064
Blood Cancer J. 2017 Dec 15;7(12):649
pubmed: 29242558
Br J Haematol. 2017 Aug;178(4):534-546
pubmed: 28439875
Sci Immunol. 2016 Aug;1(2):
pubmed: 28417112
Leuk Lymphoma. 2013 Oct;54(10):2215-8
pubmed: 23311294
Leuk Lymphoma. 2018 May;59(5):1127-1132
pubmed: 28792255
J Clin Invest. 2011 Jul;121(7):2723-35
pubmed: 21633165
Innate Immun. 2017 Jul;23(5):413-423
pubmed: 28399692
Annu Rev Pathol. 2014;9:181-218
pubmed: 24050624
Blood. 2019 May 16;133(20):2159-2167
pubmed: 30898857
Open Biol. 2012 Nov;2(11):120134
pubmed: 23226600